Genetic Susceptibility to Radiation Induced Thyroid Cancer

Case control on thyroid cancer occuring in a cohort of 7300 subjects treated during their childhood, mostly by radiotherapy, for a skin Angioma at Gustave Roussy, Villejuif France between 1947 and 1973.

This case control study, which is included in a larger european project, aims to investigate the DNA variant interacting with the risk of radiation induced thyroid cancer after irradiation.

The sutdy is planed to include about 30 cases and 30 controls. Matching criteria are date of birth, gender, and age at irradiation.

Study Overview

• Status: Unknown
• Conditions: Thyroid Neoplasms; Radiation Exposure; Genetic Susceptibility

• Study Type: Observational
• Enrollment (Anticipated): 60

Contacts and Locations

• Study Contact: Name: Monia Zidane, MD; Phone Number: +33142115093; Email: monia.zidane@gustaveroussy.fr
• Study Contact Backup: Name: Nadia Haddy, PhD; Phone Number: +33142115601; Email: nadia.haddy@gustaveroussy.fr

Study Locations

• France
  • Val De Marne
    • Villejuif, Val De Marne, France, 948000
      • Recruiting
      • Gustae Roussy
      • Contact: Monia Zidane, MD; Phone Number: +33142115093; Email: monia.zidane@gustaveroussy.fr
      • Contact: Françoise Terrier; Phone Number: +33142114140; Email: Francoise.terrier@gustaveroussy.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Cohort of subjects treated for a skin hemangioma at Gustave Roussy Institute from 1947 to 1973, mostly by radiotherapy.

Description

Inclusion Criteria:

Diganosis of thyroid cancer during the followup or selected as a control matched on gender, date of birth and age at skin hemangioma diagnosis.

Exclusion Criteria:

No available adress Refusal

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Differentiated thyroid carcinoma	Number of differentiated thyroid carcinoma occuring in a cohort of subjects treated for a skin hemangioma during the follow-up	From hemangioma diagnosis to the end of the followup, in average 45 years after hemangioma diagnosis

Collaborators and Investigators

• Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
• Investigators: Principal Investigator: Florent de Vathaire, PhD, Institut National de la Santé Et de la Recherche Médicale, France

Study record dates

Study Major Dates

• Study Start (Actual): September 22, 2019
• Primary Completion (Anticipated): April 30, 2020
• Study Completion (Anticipated): April 30, 2020

Study Registration Dates

• First Submitted: October 9, 2019
• First Submitted That Met QC Criteria: October 23, 2019
• First Posted (Actual): October 25, 2019

Study Record Updates

• Last Update Posted (Actual): October 25, 2019
• Last Update Submitted That Met QC Criteria: October 23, 2019
• Last Verified: October 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Neoplasms by Site; Endocrine System Diseases; Disease Attributes; Endocrine Gland Neoplasms; Head and Neck Neoplasms; Thyroid Diseases; Disease Susceptibility; Thyroid Neoplasms; Genetic Predisposition to Disease
• Other Study ID Numbers: C 17-69